The hPSCreg is managed by the partners Anna Veiga (CMR[B]), Glyn Stacey (UKSCB) and Andreas Kurtz (BCRT).
Berlin-Brandenburg Center for Regenerative Therapies
The Berlin-Brandenburg Center for Regenerative Therapies (BCRT) is an interdisciplinary translational center with the goal of enhancing endogenous regeneration by cells, biomaterials, and factors which can be used to develop and implement innovative therapies and products.
At the BCRT clinicians and researchers are working closely together on a personalized medicine that depends on the early recognition of patients individual healing potential. The primary focus of the BCRT is on diseases of the immune system, the musculoskeletal system, the cardiovascular system and the kidney for which currently only unsatisfactory treatment options are available. Early cooperation with industry, health insurers and regulatory authorities as well as other external partners boosts the chances of exploiting new methods and provides access to flexible financing options.
Center of Regenerative Medicine in Barcelona
The Center of Regenerative Medicine in Barcelona (CMRB) was founded in 2004 by virtue of an agreement between the Health Department of the Catalonian Government and the Carlos III Health Institute (ISCIII) of the Spanish Ministry of Science and Innovation. The fundamental mission of CMR[B] is to advance the implementation of regenerative medicine strategies by conducting research of excellence on the generation of pluripotent stem cells and on the mechanisms that control their differentiation toward clinically relevant cell types. CMR[B] is located in the Barcelona Biomedical Research Park (PRBB), which hosts seven centers of scientific excellence devoted to study the most relevant questions in contemporary life sciences and biomedicine, from the molecular to the population perspective. PRBB hosts more than 1400 researchers and provides infrastructure and facilities to the centers located within. CMR[B] is composed of a Research Center, which carries out basic and translational projects on regenerative medicine research, Core Facilities equipped with highly sophisticated technologies and expert staff, and the Stem Cell Bank (BLC). An Ethics Review Board (CEIC) provides support to researchers on project documentation and reviews all applications involving pluripotent stem cell research.
The Stem Cell Bank (BLC) is a functional unit of the CMR[B] dedicated to the storage and banking of human ESCs and iPSCs. It works as a node of the Spanish National Bank of Cell Lines (BNLC). The Stem Cell Bank mission is the production, test, banking and release of research grade pluripotent stem cell lines to all researchers that hold an approved project on stem cells.
The main areas of research at CMR[B] are:
- Generation of clinically safe human pluripotent stem cells
- Controlled differentiation of human pluripotent stem cells
- Modeling human disease through iPS cell technology
- Understanding the molecular mechanisms of cell reprogramming
- Understanding the bases of natural regeneration
UK Stem Cell Bank
The UK Stem Cell Bank (UKSCB) was established in 2003 to store, characterise and supply ethically approved stem cells for medical research and treatment. It was the first government funded public service collection of stem cells and it has played an important role in developing and maintaining standards in the UK and internationally. It is a research council (MRC/BBSRC) funded project hosted by the National Institute for Biological Standards and Control (a centre of the UK regulatory body MHRA).
The Bank currently mainly holds human ES cells. However, it can bank any type of human stem cell line, including those derived from fetal tissue or adult tissue, and it does hold some examples of these. The Bank has also produced new human induced pluripotent stem cell lines (iPSC) and is in the process of accepting more than 30 new “clinical grade” human ES cell lines, which meet the tight UK and European regulatory standards required for use of the cells in future therapies for patients.
In addition to testing, holding and distributing cells, the Bank is involved in a range of UK and international research programmes. The Bank’s researchers have also provided independent qualification of protocols for using human ES cells and human iPS cells to make neural (brain) cells for medical research, have developed new microbial agent detection systems and enhanced cryopreservation methods to reduce contamination and improve storage of cells. The Bank’s activities have a far broader reach than simply providing cells for research. It collaborates with researchers and regulators to find solutions to regulatory challenges for the use of stem cells in medical applications, makes significant contributions to the development of international standards for stem cell culture and characterisation and plays an important role in training researchers
Commitee of National Representatives
Leading scientists from all countries where the derivation or generation of human pluripotent stem cells (hPSC) or research with these cells is currently allowed form the National Contacts Group (NCG). It constitutes the bridge between hPSCreg and the national research communities and provides updates on the scientific and legal developments in their countries as well as on the cell lines that are available. If new countries become eligible to hPSC derivation or research, then national representatives will be appointed by the Project Management for these countries to join the NCG.
|Australia||not available||Monash University|
|Belgium||not available||Centre for Medical Genetics, Vrije Universiteit Brussel, Research|
|Brazil||not available||Laboratório Nacional de Células-Tronco Embrionárias (LaNCE) – SP . Depto. Genética e Biologia Evolutiva Universidade de São Paulo. Rua do Matão, 277 sala 350 São Paulo, SP 05508-900|
|Czech Republic||not available||Faculty of Medicine Masaryk University|
|Denmark||not available||Bioneer A/S|
|Finland||not available||Academy of Finland|
|France||not available||Agence de la Biomedecine|
|Germany||not available||Berlin-Brandenburg Center for Regenerative Therapies|
|Hungary||not available||Agricultural Biotechnology Center|
|India||not available||Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR)|
|Iran||not available||Department of Stem Cells, Royan Institute|
|Israel||not available||Hadassah University Medical Center|
|Italy||not available||Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases, University of Milan|
|Japan||not available||National Institutes of Biomedical Innovation|
|Netherlands||not available||Leiden University Medical Center|
|Norway||not available||University Hospital of Trondheim|
|Portugal||not available||Faculty of Medicine of Lisbon and the Instituto de Medicina Molecular|
|South Korea||not available||National Institutes of Health|
|Spain||not available||ISC III. Subdirección Gral de Investigación en Terapia Celular y Medicina Regenerativa. Madrid|
|Sweden||not available||Linköping University|
|Switzerland||not available||University of Geneva|
|Turkey||not available||Embriyoloji Laboratuarlar_ Direktörü Bahçeci Sa_l_k Grubu Hakk_ Yeten Cad. No:11 Kat 3 Terrace Fulya 34365 Istanbul|
|United Kingdom||not available||UK Stem Cell Bank|
|United States||not available||WiCell and Wicell Bank|
An independent Ethics Advisory Group ensures that all activities of hPSCreg are in compliance with the fundamental ethical principles applicable to the field of hESC and hiPSC research and use. It liaises closely with the Project Management and the Committee of National Representatives and will issue appropriate ethical guidance. The Ethics Advisory Group partner the Ethics Working Party (EWP) of the International Stem Cell Initiative (ISCI).
Rosario Isasi is currently a Research Associate at the Centre of Genomics and Policy, Faculty of Medicine, at McGill University. Mrs. Isasi has built an international reputation as a scholar with particular expertise in the area of comparative law and ethics regarding regenerative medicine, human genomics and stem cell research.
Mrs. Isasi has extensive experience in both educational and academic research on the socio-ethical and legal implications (ELSI) arising in the context of research and clinical translation surrounding novel therapies. She has significant expertise in providing ongoing ELSI consultation to multidisciplinary research consortia to assist them in the prospective identification and management of actual or emerging ELSI issues and challenges. Her work contributes to the development of evidence-based ethical guidelines and policy.
Closely related to her academic work is her role as an ethics and policy adviser to government, professional and international bodies, such as the United Nations, where she played an active role in the adoption of the UN Declaration on Human Cloning. Most recently, she contributed to the development of harmonized ELSI and educational tools for Canadian Blood Services’ National Public Cord Blood Bank, the Centre for the Commercialization of Regenerative Medicine (CCRM) and to the Bioethics Education Project of the Royal College of Physicians and Surgeons of Canada.
Rosario Isasi holds many leadership roles in major international initiatives. She is the Academic Secretary of the International Stem Cell Forum Ethics Working Party and leads the Governance Working Group of the International Stem Cell Baking Initiative. She is a member of the Hinxton Group, an international Consortium on Stem Cells, Ethics and Law. She is also a member of the Legal and Human Rights Advisory Board of the Genetics Policy Institute; and member of the advisory board of Global Lawyers and Physicians, a transnational professional association of lawyers and physicians working together to promote human rights and health.
Mrs. Isasi was the first post-doctoral fellow at the Canadian Program on Genomics and Global Health at Joint Centre for Bioethics, University of Toronto. She received further post-doctoral training at the Genetics and Society Project, Centre de Recherche en Droit Public, Université De Montréal. She holds her J.D. from the Pontifical Catholic University of Peru, where she practiced corporate and health law. She received her Masters of Public Health from Boston University, USA.
Scientific Advisory Board
The scientific advisory board (SAB) is formed by a group of leading scientists in the areas of stem cell research, stem cell banking and registration. The SAB guides the hPSCreg management on the strategic and international goals.